The combination of pembrolizumab and enfortumab vedotin shows promise as a first-line therapy for advanced urothelial carcinoma. Enfortumab vedotin targets nectin-4, in turn enhancing T cell and natural killer cell activity, inhibiting immunosuppressive pathways and impeding tumour evasion. This synergy with pembrolizumab shows potential in enhancing immunotherapy for these patients.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Powles, T. B. et al. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann. Oncol. 34 (Suppl. 2), S1340 (2023).
Chikuma, S. et al. PD-1-mediated suppression of IL-2 production induces CD8+ T cell energy? in vivo. J. Immunol. 182, 6682–6689 (2009).
Milella, M. et al. Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. Br. J. Cancer 79, 770–779 (1999).
Sakatani, T. et al. IFN-gamma expression in the tumor microenvironment and CD8-positive tumor-infiltrating lymphocytes as prognostic markers in urothelial cancer patients receiving pembrolizumab. Cancers 14, 263 (2022).
Baker, S. C. et al. The urothelial transcriptomic response to interferon gamma: implications for bladder cancer prognosis and immunotherapy. Cancers 14, 5295 (2022).
Liu, Y. et al. Role of nectin-4 protein in cancer (Review). Int. J. Oncol. 59, 93 (2021).
Chen, Z. et al. Comprehensive analysis revealed that CDKN2A is a biomarker for immune infiltrates in multiple cancers. Front. Cell Dev. Biol. 9, 808208 (2021).
Challita-Eid, P. M. et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 76, 3003–3013 (2016).
Gray, E. et al. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models. J. Immunother. Cancer 11, e007572 (2023).
Ganguli, N., Kumari, P., Dash, S. & Samanta, D. Molecular and structural basis of TIGIT: nectin-4 interaction, a recently discovered pathway crucial for cancer immunotherapy. Biochem. Biophys. Res. Commun. 677, 31–37 (2023).
Author information
Authors and Affiliations
Contributions
M.S., F.M. and J.B. researched data for the article. All authors contributed substantially to discussion of the content. M.S. wrote the article. All authors reviewed and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
M.S. has received research support and honoraria from Janssen, Bristol Myers Squibb, Ipsen, MSD, Astellas and Bayer, all unrelated to the present paper. F.M. has received research support and/or honoraria from Advanced Accelerator Applications, Astellas, AstraZeneca, Bayer, BMS, Janssen, Ipsen, MSD and Pfizer outside the submitted work. L.C. has received honoraria for advisory boards, speaker engagements and scientific consultancy for educational purposes from AstraZeneca, EISAI, MSD, Ipsen, BMS and A.A.A., and is a past MSD employee in Medical Affairs. O.F. received honoraria from Novartis, Janssen, Merck and Pfizer for consultations and lectures unrelated to this project. S.B. has received honoraria for speaking at scientific events and advisory roles from AstraZeneca, Bristol Myers Squibb, Ipsen, Merck, Eisai, MSD, Novartis and Pfizer, and research funding from Novartis and Pfizer. J.B. reports institutional and personal, paid and unpaid support for research, advisory boards, consultancy and honoraria (all outside this work) from AstraZeneca, Bristol Myers-Squibb, EMD Serono, Merck, Pfizer, Roche, Sanofi/Aventis, Up-To-Date and CME events (Peerview, OncLive), outside the submitted work; no speaker’s bureau. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Santoni, M., Takeshita, H., Massari, F. et al. Pembrolizumab plus enfortumab vedotin in urothelial cancer. Nat Rev Urol (2024). https://doi.org/10.1038/s41585-024-00858-y
Published:
DOI: https://doi.org/10.1038/s41585-024-00858-y